|
|
 |
|
Viewing report
|
|
|
|
HIV - Simplicity And Survival
Datamonitor, Aug 2005, Pages: 218
Despite accounting for only 1% of global pharmaceutical sales, HIV antiretrovirals have experienced rapid growth between 2000-2004, accounting for $6.6 billion in global sales. Enthusiasm for new once daily FDCs and PIs such as Reyataz has rendered the market for first-line naïve patients a battleground where simplicity wins. Even older flagship products such as Combivir are now under threat.
Scope
- Examination of drivers and resistors to prescription of new FDCs - pricing analysis and opinion leader perception of short and long term toxicities
- Coverage of FDA approval of Boehringer Ingelheims Aptivus (tipranavir) - future lessons for clinical studies in highly treatment experienced patients
- Assessment of the impact of generic antiretrovirals - case analysis of generic didanosine, FDA tentative approval of NNRTIs, efavirenz and nevirapine
- In-depth regional sales forecasts of marketed and pipeline drugs from 2005 to 2015 with full event analysis
Highlights
Our opinion leader research has revealed that in the majority of Western markets the major route of HIV transmission is changing. Most reported increased presentation of individuals believed to have been infected by heterosexual contact. In countries such as France, immigrants from Sub-Saharan Africa continue to dominate new diagnoses.
In 2004, the global market for HIV antiretrovirals was valued at $6.6 billion with the US accounting for around 70% of value. In Europe, France is the largest market valued at around $600m. Despite an increase in commercial value, most markets apart from the UK have experienced a decline in standard unit volume driven by uptake of FDC products.
Boehringer Ingelheims FDA approval for Aptivus (tipranavir) raises the PI class to nine members. Despite challenges during clinical development, testing in a highly experienced population and 24-weeks data using a surrogate for efficacy, tipranavirs approval signals a high need for additional agents to Fuzeon (enfuvirtide) in this patient group.
Reasons to Purchase
- Assess the value and volume dynamics of HIV antiretrovirals on a regional level with a 5 year retrospective view
- Understand the pending impact of patent expiries and generic incursion on the antiretrovirals market, including product-specific case studies
- Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2005 to 2015
Customers who bought this item also bought
Commercial Insight: HIV - Simplicity and Survival
HIV - Benchmarking Rapid Antiretroviral Uptake
Commercial Insight: HIV - Reshaping Treatment Paradigms
Commercial Insight: HIV - Change of Guard
Forecast Insight: HIV - Cross-class fixed dose combinations drive continued growth
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
The Global HIV/AIDS Market Outlook to 2012
Pipeline Insight: HIV - The Age of Convenience
Commercial Insight: HIV - From the Naïve to the Complex
Stakeholder Insight: HIV Therapy Dynamics
Pipeline Insight: HIV - Enter the New Generation Inhibitors
Pipeline Insight: HIV - Hold Your Horses
|
|
|
|
